GREY:IMVIQ - Post by User
Comment by
Breakthorough1on May 17, 2018 6:52am
143 Views
Post# 28043757
RE:RE:RE:Am I wrong?
RE:RE:RE:Am I wrong?Hi, PoorOpinion:
What you say does completely make sense. Just one of the two patients in green can have achieved SD after the 5 of december, and that's why then it was counted as one of the three PD.
But, without overinterpreting the results, two things are clear:
1) Time works in favour of clinical efficacy. And actually this was highlighted two dys ago by Pierre Labb himself here (he actually talks about two years frame): https://www.streetwisereports.com/article/2018/05/16/cancer-in-the-crosshairs-imv-looks-to-deliver-immunotherapy-a-new-way.html
2) The results in the 300 mg cohort should not be worse. They have many times highlighted that 300mg is the proper clinical dose of Epacadostat, and I guess that if they do so (knowing that it creates expectations and that they know how the trial is going on) they will not do it to disappoint investors later.
Everyhting looks really promisisng. GLTA